© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 8, 575-577,
April 18, 2001
© 2001 Oxford University Press
NEWS |
Chemoprevention: Can Industry and Academia Collaborate?
The advertisements are hard to miss in most medical journals. Full-page color spreads of DNA helixes, robotic humans, and other high-tech images promise an automated medical future. All are from pharmaceutical or biotech companies; all pledge their corporate commitment to build a brave new world of molecular medicine.
As this new molecular world comes into tighter focus, many experts predict that so, too, will the promise of cancer chemoprevention. If true, oncologists would no longer spend their days coping with what we now call cancer. They would have the molecular tools to detect carcinogenesis, the early, multi-step process that leads to cancer, and a pharmacy of tumor-suppressing chemicals that snuff out developing tumors well before they turn invasive and deadly.
Though the promise of chemoprevention far outpaces the science, industry is slowly, but surely, buying into its future, and with good reason.
Tall Tasks
Patent Protection